The management of Gitelman Syndrome (GS) is predominantly aimed at alleviating symptoms and rectifying electrolyte imbalances through the supplementation of potassium and magnesium, alongside the employment of ACE inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and aldosterone antagonists. The gene discussed is ACE; the disease is Gitelman syndrome.